Suggestions
Ben Freeberg
Oncology Ventures, Managing Partner
Ben Freeberg is the Founder and Managing Partner of Oncology Ventures, a venture capital fund focused on investing in early-stage startups that improve cancer care through data and technology. Established in November 2022, Oncology Ventures aims to tackle the high costs and complexities associated with cancer treatment by supporting companies that enhance early detection and optimize treatment plans, rather than investing in drug development or medical devices.12
Background and Experience
Freeberg has a rich background in healthcare investment, having previously served as Vice President at Optum Ventures, where he was involved with significant healthcare technology investments. He was also the first employee at Alpha Partners, a growth equity firm, and held key roles at Thyme Care, a cancer care startup that raised substantial funding from notable investors.134
His personal experience as a cancer survivor, having been diagnosed with Stage 3a cancer, profoundly influences his approach to investing. Freeberg's journey through cancer treatment has shaped his understanding of the challenges faced by patients and startups in the oncology space. He emphasizes the importance of investing in solutions that reduce healthcare costs and improve patient outcomes.23
Oncology Ventures
Oncology Ventures recently closed its inaugural fund with $30 million in committed capital, attracting investments from prominent healthcare institutions. The fund focuses on startups that leverage data and technology to enhance cancer care, with a particular interest in areas such as early detection, care navigation, and survivorship support.234
Freeberg's leadership is characterized by a proactive investment strategy, with the firm already backing several startups addressing critical gaps in cancer care.34 His commitment to improving oncology outcomes is further supported by an advisory board that includes experts from various sectors of healthcare and venture capital.34
In summary, Ben Freeberg combines his professional expertise in venture capital with his personal experience as a cancer survivor to lead Oncology Ventures, focusing on innovative solutions that aim to transform cancer care.
Highlights
Thank you to TechCrunch and Reuters for covering Oncology Ventures' oversubscribed $30M Fund 1!
Appreciate the support from all of our Limited Partners (City of Hope, Cardinal Health, Moffitt Cancer Center, Atlantic Health System, New York Cancer & Blood Specialists, Astera Cancer Care, Debiopharm, Ohio State University Physicians, The Center for Cancer and Blood Disorders, Amkan Ventures and more)...
to help improve cancer care and research through our incredible portfolio companies: OncoveryCare, Gabbi, Health Universe, Inc, Reimagine Care, Concr, IgniteData and mPATH Health.
TechCrunch: https://lnkd.in/gCiUGVcz
Reuters: https://lnkd.in/gdmGH8MU
Oncology Ventures is excited to announce its 6th investment, IgniteData. We look forward to partnering with Zach Taft, Steven Tolle, Richard Yeatman, Dan Hydes and team as they bring much needed efficiency to oncology clinical trial infrastructure.
Check out our investment thesis here: https://lnkd.in/eqUuNZU5
Separately, we are building out our downstream capital database for VCs. If you are a VC firm that wants to be included in our curated portfolio company updates, please e-mail / DM us your investment size, stage and any core thesis areas you are excited about.
